Literature DB >> 29864751

Schizophrenia and Physical Comorbidity.

Ivona Šimunović Filipčić1, Igor Filipčić.   

Abstract

Schizophrenia is a severe psychiatric disorder increasingly recognized as a systemic disorder. In addition to the burden and suffering caused by the mental illness itself, individuals with schizophrenia have a high risk for physical illnesses. The life expectancy gap remains 13 to 30 years wider in people with schizophrenia compared to the general population. This premature mortality is caused largely by deaths due to cardiovascular disease, cancer, diabetes mellitus, and other natural causes, poor diagnosis and treatment, and insufficient prevention of modifiable risk factors. Although the links between schizophrenia and physical illnesses are well established, in clinical practice, physical illnesses in patients with schizophrenia are often overlooked, and the mortality gap between general population and people with schizophrenia continues to widen. The physical health of people with schizophrenia is commonly self-neglected but also ignored by people around them and by health systems, resulting in significant physical health disparities and limited access to health services. The root of the problem of insufficient healthcare appear to lie in interrelated contributory factors from illness, patients, and medical and mental healthcare system. Furthermore, a growing body of literature has been indicating the effect of the chronic physical illness on the treatment outcome of psychosis. Premature mortality and disability could be reduced if there was a greater focus on the implementation of strategies that effectively prevent modifiable risk factors from the first psychotic episode and enhance early recognition of physical illnesses, reduce the burden of physical comorbidity and lead to improved health outcomes. Ultimately, to improve treatment outcome and to reduce the suffering of people with schizophrenia, it is crucial to treat physical comorbidity promptly and assertively from the appearance of the first symptoms of the psychotic disorder. The integrative approach and collaborative care within all levels of healthcare providers should be the imperative in clinical practice.

Entities:  

Mesh:

Year:  2018        PMID: 29864751

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  9 in total

1.  The prevalence and independent influencing factors of obesity and underweight in patients with schizophrenia: a multicentre cross-sectional study.

Authors:  Juan Wang; Yulong Zhang; Yating Yang; Zhiwei Liu; Lei Xia; Wenzheng Li; Zhongxiang Li; Xinhui Xie; Wenfeng Deng; Kai Zhang; Huanzhong Liu
Journal:  Eat Weight Disord       Date:  2020-06-17       Impact factor: 4.652

2.  Predictors of successful move-on to more independent accommodation amongst users of the community mental health rehabilitation team: a prospective cohort study in inner London.

Authors:  Karen Pui Kei Chan; Kay Kathryn; Artemis Igoumenou; Helen Killaspy
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-07-05       Impact factor: 4.328

3.  An unusual case of oral surgical management in a patient with isovaleric acidemia and schizophrenia: A case report.

Authors:  Sho Miyamoto; Edward Hose Ntege; Yasutsugu Chinen; Takahiro Goto; Jumpei Shirakawa; Shimpei Goto; Toshihiro Kawano; Yusuke Shimizu; Koichi Nakanishi; Hiroyuki Nakamura
Journal:  Biomed Rep       Date:  2022-06-07

4.  Epilepsy, dissociative seizures, and mixed: Associations with time to video-EEG.

Authors:  Wesley T Kerr; Xingruo Zhang; Chloe E Hill; Emily A Janio; Andrea M Chau; Chelsea T Braesch; Justine M Le; Jessica M Hori; Akash B Patel; Corinne H Allas; Amir H Karimi; Ishita Dubey; Siddhika S Sreenivasan; Norma L Gallardo; Janar Bauirjan; Eric S Hwang; Emily C Davis; Shannon R D'Ambrosio; Mona Al Banna; Andrew Y Cho; Sandra R Dewar; Jerome Engel; Jamie D Feusner; John M Stern
Journal:  Seizure       Date:  2021-02-09       Impact factor: 3.184

Review 5.  The Role of Adiponectin in the Pathogenesis of Metabolic Disturbances in Patients With Schizophrenia.

Authors:  Cynthia Yi-An Chen; Kah Kheng Goh; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Front Psychiatry       Date:  2021-01-20       Impact factor: 4.157

6.  Is it possible to stage schizophrenia? A systematic review.

Authors:  Clara Martínez-Cao; Lorena de la Fuente-Tomás; Ainoa García-Fernández; Leticia González-Blanco; Pilar A Sáiz; María Paz Garcia-Portilla; Julio Bobes
Journal:  Transl Psychiatry       Date:  2022-05-11       Impact factor: 7.989

7.  Transient drop in the neutrophil count during COVID-19 regardless of clozapine treatment in patients with mental illness.

Authors:  Gabriel Vallecillo; Josep Marti-Bonany; Maria José Robles; Joan Ramón Fortuny; Fernando Lana; Victor Pérez
Journal:  Rev Psiquiatr Salud Ment (Engl Ed)       Date:  2022 Apr-Jun

8.  The impacts of the COVID-19 pandemic on treatment-resistant schizophrenia patients having followed virtual reality therapy or cognitive behavioural therapy: a content analysis.

Authors:  Alexandre Hudon; Nayla Léveillé; Katerina Sanchez-Schicharew; Laura Dellazizzo; Kingsada Phraxayavong; Alexandre Dumais
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

9.  Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.

Authors:  Preeya J Patel; Christian Weidenfeller; Andrew P Jones; Jens Nilsson; Jay Hsu
Journal:  Neurol Ther       Date:  2020-10-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.